Though Texas will join 26 other states in defaulting to a federal marketplace for purchasing health insurance — a major component of the Affordable Care Act — it is one of only six that will not enforce new health insurance reforms prescribed by the law. It's a decision some say could lead to confusion over who's responsible for protecting Texas insurance consumers.
Because Texas did not create its own state-based marketplace, known as a health insurance exchange, under the Affordable Care Act, it must use a federally facilitated one instead. By federal law, the state must enforce provisions and regulations related to the insurance exchange and market reforms unless it notifies the federal government that it cannot or will not. If a state does not enforce those reforms, the federal Centers for Medicare and Medicaid Services will step in to do it.
Texas, Arizona, Alabama, Missouri, Oklahoma and Wyoming have all notified the federal government that they will not be policing the health law. John Greeley, a spokesman for the Texas Department of Insurance, said his agency cannot enforce regulations tied to the federal insurance exchange or market reforms because it is not authorized to do so.
"We can't act on anything that doesn't exist in state law," he said.
Officials with CMS, who sent a letter to TDI acknowledging the state's decision, declined to comment for this story.
Stacey Pogue, a health policy analyst with the liberal Center for Public Policy Priorities, said she doesn't believe TDI's hands are tied. In the past, she said, the agency has responded to federal laws by "taking actions that ensure that they do have oversight."
The practical effects of the state's decision are not entirely clear yet. In the first show of autonomy, Texas was not required to comply with a federal request for information about its insurance plans. Most states defaulting to the federal health insurance exchange had to submit that information by July 31.
In the states that will not enforce the exchange and market reforms, the federal government will have to review insurance forms and respond to consumer complaints about health insurance, said Kevin Lucia, an assistant research professor with the Georgetown University Health Policy Institute’s Center on Health Insurance Reforms. Those duties, he added, are “typically reserved for state insurance departments.”
Pogue said the state's decision could create an “administrative burden” for insurance plans and could result in confusion for Texans who purchase health insurance under the federal exchange. For instance, she said, if people worry their insurance providers are discriminating against them based on their gender — a practice banned by the federal reforms — they may not know whether to report a complaint to CMS or to TDI.
“There’s all this opportunity to be bounced back and forth, which is a burden for consumers,” she said. If consumers have to report insurance violations to the federal government, that could prevent TDI from having a complete picture of consumers’ experience with insurance providers, she added.
“Consumers can be experiencing a lot of problems on the market that the state regulator doesn’t know about,” Pogue said.
Greeley said TDI has worked to make sure “insurers understand what their responsibilities are” under the ACA. And he said even if the state does not enforce federal regulations, TDI will still work to protect insurance consumers.
“Anybody that buys an insurance policy in Texas — no matter what line or how they got to it — can come to the Texas Department of Insurance for their questions,” he said.
David Gonzales, executive director of the Texas Association of Health Plans, said it’s unclear what impact the state's decision could have on insurance companies.
“I suspect it will be more of a burden for some plans than for others,” he said.
Pogue said inefficiencies could stem from the state’s refusal to enforce insurance reforms. TDI is the agency best equipped to regulate insurance plans in Texas, she said.
“Without a doubt they are the appropriate body,” she said.
_____________________________________
Source: Texas Tribune (Luthra, 8/07)
Showing posts with label healthcare fraud. Show all posts
Showing posts with label healthcare fraud. Show all posts
Monday, August 12, 2013
Tuesday, July 3, 2012
GlaxoSmithKline to pay $3 billion to settle bribery, fraud allegations with US
The announcement by the Justice Department of a settlement with drugmaker GlaxoSmithKline of bribery allegations generated heavy media coverage last night and this morning, including more than seven minutes of coverage on network newscasts.
The CBS Evening News (7/2, story 6, 2:50, Pelley) reported, "The US government is calling it the biggest case of healthcare fraud in American history. The British drug maker GlaxoSmithKline is accused of withholding important safety information about the diabetes drug Avandia [rosiglitazone] and illegally promoting two other drugs for unapproved uses. GSK agreed to pay $3 billion in fines."
NBC Nightly News (7/2, story 4, 2:00, Williams) reported, "At the launch of asthma drug Advair prosecutors say global drug giant GlaxoSmithKline pushed the sales force to push hard even for uses not Federally approved. Today the company admitted its sales force bribed doctors to prescribe its drugs by offering such incentives as Hawaiian vacations and tickets to Madonna concerts."
ABC World News (7/2, story 4, 2:15, Muir) reported, "The goal to rev up sales as part of what prosecutors say was a culture of greed where patient safety took a back seat to profit. The government claims GSK engaged in an illegal marketing campaign where drugs were promoted for disorders where there was no medical evidence they would help. Allegations of promoting the drug Paxil for treating depression in patients under age 18 even though the FDA's has never approved it for kids."
The Los Angeles Times (7/3, Hsu) reports, "The agreement is the largest healthcare fraud settlement in history, spanning nearly every state, according to the Justice Department. It's also the largest payment ever by a drug company. The settlement is 'unprecedented in both size and scope,'" Deputy Attorney General James Cole said in a statement.
USA Today (7/2) reports, "Under the terms of the plea agreement, GSK will pay a total of $1 billion, including a criminal fine of $956,814,400. The company also will pay $2 billion to resolve civil claims under the federal government's False Claims Act. Glaxo is pleading guilty to these violations of FDA regulations, which are misdemeanors. It has set aside $3.5 billion to cover the cost of the fines and other penalties related to the government's seven-year probe of the company's marketing practices for Paxil [paroxetin], Wellbutrin [bupropion] and Avandia, three of its blockbuster drugs."
In a front-page story, the New York Times (7/3, A1, Thomas, Schmidt, Subscription Publication) reports, "The fine against GlaxoSmithKline over Paxil, Wellbutrin and Avandia makes this year a record for money recovered by the federal government under its so-called whistle-blower law. In May, Abbott Laboratories settled for $1.6 billion over its marketing of the antipsychotic drug Depakote. And an agreement with Johnson & Johnson that could result in a fine of as much as $2 billion is said to be imminent over its off-label promotion of another antipsychotic drug Risperdal."
[Contact a Texas Personal Injury Attorney if you've suffered from prescription errors]
Subscribe to:
Posts (Atom)

